AcouSort

The continued collaboration aims to further explore how AcouSort’s AcouWash technology can be adapted for the partner’s specific application including integration of design suggestions to enable the development of OEM components in the partnering company’s future cell therapy products and instruments. The second phase of the collaboration project generates revenues of EUR 130,000 to AcouSort in 2023. The continued collaboration verifies the commercial potential of AcouSort’s focus on developing technology towards OEM separation modules to be used for cell therapy solutions in clinical settings.

“We are most happy to see the continuation of this exciting project where we will have the opportunity to further develop our technology to meet the needs of the cell therapy market. The continued collaboration enables us to direct our efforts and accelerate the development towards dedicated cell therapy OEM modules”, says AcouSort’s CEO Torsten Freltoft.

This information is information that AcouSort AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted, through the agency of the contact person below, for publication on January 20, 2023, at 11:30 am.